Communiqués Summit Therapeutics Inc.

Actions

SMMT

US86627T1088

Recherche biotechnologique et médicale

Marché Fermé - 22:00:00 26/08/2026 Varia. 5j. Varia. 1 janv.
14,23 USD +6,51 % Graphique intraday de Summit Therapeutics Inc. +8,54 % -18,64 %

Communiqués

26/08 Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China BU
25/08 Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology BU
13/08 Summit Therapeutics - Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer AQ
12/08 Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer BU
05/08 Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer BU
27/07 Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 AQ
23/07 Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 BU
22/07 Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study BU
16/07 Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 BU
14/07 Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc. BU
09/06 Summit Therapeutics Announces Proposed Public Offering of Common Stock BU
04/06 Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference BU
31/05 Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the Phase 3 HARMONi-6 Slides PU
31/05 Summit Therapeutics : Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China PU
31/05 Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China BU
30/05 A randomized, active-controlled phase 3 study of ivonescimab FOLFOX versus bevacizumab FOLFOX as first-line treatment of metastatic colorectal cancer: HARMONi-GI3 PU
30/05 Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026 BU
30/04 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 BU
27/03 Health-Related Quality of Life in Patients Previously Treated With an EGFR-TKI From HARMONi: A Phase 3 Trial of Ivonescimab vs Placebo Plus Chemotherapy PU
27/03 Health-Related Quality of Life With Ivonescimab Versus Pembrolizumab for PD-L1 Positive, Non–Small Cell Lung Cancer (HARMONi-2): A Randomised, Double-Blind, Phase 3 Study in China PU
27/03 Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 BU
27/02 Summit Therapeutics to Present at Upcoming Investor Conferences BU
23/02 Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 BU
17/02 Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 BU
30/01 Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
Aucun résultat pour cette recherche
🔇